suggest a relation to many problems that are similar to symptoms. histone modifications histones are proteins that the dna chromosome are wrapped around. histones are present as an octamer (set of 8 proteins) and they can be modified through acetylation, methylation, sumoylation, ubiquitination, phosphorylation, etc. these changes can either open or close up the chromosome. thus, depending on which histone is modified and the exact process, histone modifications can either silence or promote gene expression (while dna methylation almost always silences). because the sub-field of histone modifications is relatively new, there aren't many results yet. investigations into these epigenetic regulations indicate that therapeutic pathways targeting epigenetic mechanisms like differential methylation and acetylation may be beneficial. some studies have found that patients with schizophrenia have higher levels of methylation at h3 (the 3rd histone in the octamer) in the prefrontal cortex, an area that could be related to the negative symptoms. a prominent example is the increased repressive methylation of histone 3 (h3k9me2), which has been associated with both age of disease onset and treatment resistance. it has also been shown that histone acetylation and phosphorylation is increased at the promoter for the bdnf protein, which is involved in learning and memory. more recent studies have found that postmortem brain tissue from patients with schizophrenia had higher levels of hdac, histone deacetylase, an enzyme that remove acetyl groups from histones. hdac1 levels are inversely correlated with gad67 protein expression, which is decreased in patients with schizophrenia. heritable epigenetic alterations studies have shown that epigenetic changes can be passed on to future generations through meiosis and mitosis. these findings suggest that environmental factors that the parents face can possibly affect how the child's genetic code is regulated. research findings have shown this to be true for patients with schizophrenia as well. in rats, the transmission of maternal behavior and even stress responses can be attributed to how certain genes in the hippocampus of the mother are methylated. another study has shown that the methylation of the bdnf gene, which can be affected by early life stress and abuse, is also transmittable to future generations. in addition to epigenetic effects as a result of maternal influence during important stages of neurodevelopment, studies show that nutrient deprivation can result in epigenetic modifications that are maintained from generation to generation. historically, famines are thought to cause changes in epigenetic regulation within the human genome. specifically, deprivation of nutrients is thought to alter methylation patterns in mammals, and several case studies have shown that periods of famine are positively correlated to increased incidences of schizophrenia in certain populations. babies born during periods of famine were up to twice as likely to develop schizophrenia or schizophrenia spectrum disorder. thus, researchers believe that the development of schizophrenia is linked to nutrient deprivation. the leading hypothesis for how this is accomplished is via subtle epigenetic alterations following nutrient deprivation, such as the hypermethylation of genes in neurotransmitter pathways, since it is well documented that dietary restriction has an effect on dna methylation states. this line of thinking is further supported by studies showing that deficiencies in certain nutrients, including choline, folate and vitamin b12 which are required for the creation s-adenosylmethionine (sam), are also linked with increasing the epigenetic factors associated with increased risk of schizophrenia. evidence is still mounting in this area, but the existing correlations are notably strong. environmental risks and causes while there haven't been many studies linking environmental factors to schizophrenia-related epigenetics mechanisms at this point in the field, a few studies have shown interesting results. advanced paternal age is one of the risk factors for schizophrenia, according to recent research. this is through mutagenesis, which cause further spontaneous changes, or through genomic imprinting. as the parent ages, more and more errors may occur in the epigenetic process. there is also evidence of the association between the inhalation of benzene through the burning of wood and schizophrenic development. this might occur through epigenetic changes. methamphetamine has also been linked to schizophrenia or similar psychotic symptoms. a recent study found that methamphetamine users had altered dnmt1 levels, similar to how patients with schizophrenia have shown abnormal levels of dnmt1 in gabaergic neurons. research has shown that there is not a 100% likelihood for genetically inheriting schizophrenia- as in monozygotic twin pairs, when one twin is diagnosed with schizophrenia, there is only a 50% chance that the other twin will also be diagnosed with schizophrenia. this finding shows that environmental influences play a role in the development of schizophrenia. maternal effects have also been shown to increase the rate of schizophrenia. it has been hypothesized that babies born in winter and spring have higher rates of schizophrenia than babies born in the summer and fall because of the increase in respiratory infections during the colder months. furthermore, a study showed that maternal respiratory infection increased the rate of schizophrenia "three- to sevenfold," and if the mothers would not have gotten the respiratory infection, "14 to 21% of schizophrenia cases would have been prevented." the relative amounts of pro-inflammatory and anti-inflammatory compounds found in maternal serum are associated with the onset of schizophrenia, as seen in studies in which amounts of interleukin 6 and interleukin 10, pro- and anti- inflammatory, respectively, were manipulated. it was reported that increasing the amount of interleukin 10 or decreasing the amount of interleukin 6 lessened the effects of the immune system on the fetus. these long-lasting impacts may indicate an epigenetic effects in the offspring, however, it remains unconfirmed. a 2018 study found that patients with schizophrenia had hypomethylation—associated with increased expression of a gene—of the ip6 promoter region compared to the control subjects. dna methylation patterns have been linked with increased schizophrenia risk. specifically, the hypermethylation of the promoter region has been reported to suppress expression of reelin (reln) in the frontal and prefrontal cortex. higher dna methylation levels of reln promoters has been observed in schizophrenic patients. several other genes, including gabaergic, dopaminergic, and serotonergic genes, have also been found to have different methylation in patterns in those affected by schizophrenia. those with schizophrenia have also been noted to have increased amounts of dnmt1, which is involved in the regulation of methylation at cpg sites. jaffe et al. recently found that 2104 cpg sites were differently methylated in the prefrontal cortex those with schizophrenia as compared to those without schizophrenia. most notably, the differentially methylated sites were found in genes having to do with "embryonic development, cell fate commitment, and nervous system differentiation" as well as the time period between late gestation and early life. prenatal maternal stress (pnms) is also associated with schizophrenia and schizophrenia spectrum disorders (ssd). several studies have shown that increased pnms is linked to decreased fetal growth in males who later develop ssd. it has also been found that pnms leading to increased morbidity and mortality outcomes are also associates with increased risk of ssd development in males. pnms, especially in early pregnancy, has also been associated to motor deficiencies and behavioral difficulties in the pre-morbid period before schizophrenia onset, most notably in males. one of the most interesting findings relating an environmental factor with schizophrenic epigenetic mechanisms is exposure to nicotine. it has been widely reported that 80% of patients with schizophrenia use some form of tobacco. furthermore, smoking appeared to increase cognition in individuals with schizophrenia. however, it was only a recent study satta et al.that showed that nicotine leads to decreased levels of dnmt1 in gabaergic mouse neurons, a molecule which adds methyl groups to dna. this led to increased expression of gad67. research limitations there are several limitations to current research methods and scientific findings. one problem with postmortem studies is that they only demonstrate a single snapshot of a patient with schizophrenia. thus, it is hard to relate whether biomarker findings are related to the pathology of schizophrenia. another limitation is that the most relevant tissue, that of the brain, is impossible to obtain in living, patients with schizophrenia. to work around this, several studies have used more accessible sources, like lymphocytes or germ cell lines, since some studies have shown that epigenetic mutations can be detected in other tissues. epigenetic studies of disorders like schizophrenia are also subject to the subjectivity of psychiatric diagnoses and the spectrum-like nature of mental health problems. this problem with classification of mental health problems have led to intermediate phenotypes that might be better fit. detection and treatment the advent of epigenetics as an avenue to pursue schizophrenic research has brought about many possibilities for both early detection, diagnoses, and treatment. while this field is still at an early stage, there have already been promising findings. some postmortem brain studies looking at the gene expression of histone methylation has shown promising results that might be used for early detection in other patients. however, the bulk of the translational research focus and findings have been on therapeutic interventions. therapeutics since epigenetic changes are reversible and susceptible pharmacological treatments and drugs, there is a great deal of promise in developing treatments. as many have pointed out, schizophrenia is a lifelong disorder that has widespread effects. thus, it may not be possible to fully reverse the disease. although irreversible, the lives of patients with schizophrenia can be greatly improved through treatments that alleviate symptoms. treatments like anti-psychotic medications for schizophrenia are effective, but they often have serious side effects, and medical practitioners are always looking to improve patients' treatment outcomes. recent studies indicate that it may be possible to improve upon existing treatments through epigenetic means. this provides a promising new direction for disease management. pharmaceuticals that directly affect epigenetic markers could be used to improve the efficacy of a patient's current treatment or serve as an updated treatment regiment altogether. as previously discussed, schizophrenia is associated with elevated levels of gene methylation and repressive histone marks, including h3k9me2. mood stabilizers have become a therapeutic method of interest in treating schizophrenia due to their ability to reverse epigenetic alterations like repressive histone marks. mood stabilizers that are known to target epigenetic markers associated with schizophrenia include lithium, valproate, lamotrigine, and carbamazepine. targeting histones modifications hdac (histone deacetylase) inhibitors are one class of drugs that are being investigated. studies have shown that levels of reelin and gad67 (which are decreased in schizophrenic animal models) are both upregulated after treatment with hdac inhibitors. furthermore, there is the added benefit of selectivity, as hdac inhibitors can be specific to cell type, tissue type, and even regions of the brain. valproate, a psychotropic drug, is an hdac inhibitor that is frequently used to treat patients with schizophrenia. valproate leads to both increased h3 and h4 acetylation as well as increased gad67 and reelin mrna levels in lymphocytes. lithium has also been shown to be highly effective at increasing histone acetylation and presence of gad67 and reelin transcripts in patients experiencing psychotic symptoms. hmt (histone demethylase) inhibitors also act on histones. they prevent the demethylation of the h3k4 histone protein and open up that part of the chromatin. tranylcypromine, an antidepressant, has been shown to have hmt inhibitory properties, and in a study, treatment of patients with schizophrenia with tranylcypromine showed improvements regarding negative symptoms. in early studies, imipramine, an antidepressant drug, was shown to be able to remove the repressive epigenetic mark h3k9me2. decreasing repression at this marker appears to improve treatment outcomes for patients taking antipsychotic medications. targeting dna methylation among long-term antipsychotic users, post-mortem tissue analysis finds that genes that are typically methylated in patients with psychosis are hypomethylated after lifelong antipsychotic use. in other words, anti-psychotic drugs are able to reduce methylation of genes in long-term users. removing repressive epigenetic marks is only part of how these drugs modify the epigenome of patients with psychotic symptoms. antipsychotics are associated with both the induction and inhibition of dna methylation, which can lead to the simultaneous upregulation and downregulation of different genes in patients. while significant variation in methylation patterns have been recorded in patients using antipsychotic drugs, the evidence in this area is not yet sufficient to determine the exact mechanism underlying how these drugs influence methylation. schizophrenia is a complex, multifaceted illness, and the variety of methylation patterns observed affirms this knowledge. dnmt inhibitors have also been shown to increase levels of the reeling protein and